Abstracts tagged "Bone density"

Abstract Number: 2136 • ACR Convergence 2024
Distal Radius Correlation with Femur and Lumbar Spine T-scores: A Comprehensive Analysis
Monder Lafi¹, Hamzah Amin², Muhammed Aqib Khan³ and Marwan Bukhari⁴, ¹LANCASTER UNIVERSITY, Liverpool, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³Lancaster Medical School, Lancaster, United Kingdom, ⁴University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom
Background/Purpose: Osteoporosis, defined by the WHO as a BMD reduction of 2.5 standard deviations below that of a young healthy adult, is a major public…
Abstract Number: 0030 • ACR Convergence 2024
The Impact of Treadmill Exercise on Various Stages of Osteoarthritis Progression in a Murine Osteoarthritis Model
Mengcun Chen¹, Mingshu Cui², Yangmei Yang³ and Bin Wang¹, ¹Thomas Jefferson University, Philadelphia, PA, ²Thomas Jefferson University, Philadelpha, ³Thomas Jefferson University, Philadephia
Background/Purpose: Evidence supports the benefits of exercise on joint health and its protective effects against osteoarthritis (OA) progression [Allen J, A&R, 2010]. However, most animal…
Abstract Number: 2141 • ACR Convergence 2024
Glucocorticoid Therapy-Associated Bone Fractures Are Associated with Osteoporosis Underscreening in Patients with Rheumatoid Arthritis
Marlene Marte Furment¹ and Andras Perl², ¹SUNY Upstate Medical University, Syracuse, NY, ²SUNY, Syracuse, NY
Background/Purpose: The majority of bone loss happens within 6 months of glucocorticoid treatment. Per the 2022 American College of Rheumatology (ACR) Glucocorticoid-Induced Osteoporosis Guidelines it…
Abstract Number: 0415 • ACR Convergence 2024
Prevalence and Risk Factors of Low Bone Mineral Density in Children with Juvenile Idiopathic Arthritis
narendra bagri, Sushain Kalsotra, vandana jain, Manisha Jana, Maroof Ahmed Khan, Yashdeep Gupta and Sumit Kumar Das, All India Institute of Medical Sciences, New Delhi, Delhi, India
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatological disease in children less than 16 years of age. Various factors have been suggested…
Abstract Number: 2142 • ACR Convergence 2024
Comparison of Bone Mineral Density at the Distal Radius, Hip, and Lumbar Spine in Female Patients Undergoing Surgery for Proximal Femur or Distal Radius Fractures: Implications for Osteoporosis Diagnosis
KEN NAKASEKO, Department of Orthopaedic Surgery and Rheumatology, Kuwana City Medical Center, Kuwana Mie, Japan
Background/Purpose: Osteoporosis is often diagnosed based on bone mineral density (BMD) measurements at the hip or lumbar spine. However, our previous study reported that 38%…
Abstract Number: 1029 • ACR Convergence 2024
An Analysis of Osteoporosis Screening in Males vs. Females Across Lehigh Valley Health Network
Benjamin Wolff¹, Ryan Bigelsen², Kathryn Zaffiri², Susan Kim³ and Philip Dunn⁴, ¹Lehigh Valley Health Network, Macungie, PA, ²Lehigh Valley Health Network, Allentown, PA, ³Lehigh Valley Hospital Network, Allentown, PA, ⁴Lehigh Valley Health Network, Emmaus, PA
Background/Purpose: Osteoporosis is a widely recognized disease of the bone where bone mineral density is decreased leading to increased risk for fracture. Bone mineral density…
Abstract Number: 2143 • ACR Convergence 2024
Analysis of Effectiveness and Safety of Romosozumab in Patients with Very High Risk of Fracture in a Spanish Population
Marina soledad Moreno Garcia¹, Roxana González Mazario², yedra uson Rodriguez³, Erardo meriño Ibarra⁴, Emilio Giner⁵, Juan Carlos Cobeta García⁶, Marilia Arce Benavente⁷, maria Dolores Fábregas canales⁸, Julia Ullier Bellmunt³, Giuliano Boselli³, pilar martinez Valles⁷, Jorge Juan Fragío Gil⁹, carlos Vazquez Galeano⁷ and Ana Turrion Nieves¹⁰, ¹hospital Miguel Servet . Zaragoza, Zaragoza, Aragon, Spain, ²Hospital General de Valencia, Valencia, Comunidad Valenciana, Spain, ³hospital miguel servet, zaragoza, Aragon, Spain, ⁴Hospital San Jorge Huesca, zaragoza, ⁵Hospital Royo Villanova, Teruel, Spain, ⁶Hospital Ernest Lluch, zaragoza, ⁷hospital miguel servet, Zaragoza, ⁸Hospital de Barbastro, Huesca, Spain, ⁹Hospital General Universitario, Valencia, Comunidad Valenciana, Spain, ¹⁰Rheumatology Department, Hospital Universitario Virgen de la Vega, Salamanca, Spain
Background/Purpose: Excluding clinical trials, there is limited evidence on the effect of 12 months of romosozumab treatment on increasing bone mineral density (BMD) in real-world…
Abstract Number: 0860 • ACR Convergence 2023
Vagus Nerve Stimulation Enhances Bone Morphology in a Rodent Model of Central Nervous System Inflammation
Chandramohan Natarajan¹, Julia Lucchino¹, David Chenoff² and Yaakov Levine¹, ¹SetPoint Medical, Valencia, CA, ²SetPoint Medical, Sausalito, CA
Background/Purpose: Electrical stimulation of the vagus nerve activates the inflammatory reflex to inhibit cytokines and decrease clinical signs and symptoms of chronic inflammatory disease such…
Abstract Number: 1185 • ACR Convergence 2023
Soluble Buffered Alendronate After Denosumab Discontinuation in Erosive Hand OA Patients
Tine Vanhaverbeke¹, Dirk Elewaut² and Ruth Wittoek¹, ¹Dept. of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Belgium, ²Ghent University and VIB Center for Inflammation Research, Ghent, Belgium
Background/Purpose: In osteoporotic patients, discontinuation of denosumab is associated with a rapid increase in bone turnover and bone loss. Denosumab was recently proven to have…
Abstract Number: 1996 • ACR Convergence 2023
Variation in Dual-energy X-ray Absorptiometry Reporting: A National Survey of Veterans Health Administration Clinics
Karla Miller¹, Melissa Steffen², Kimberly McCoy², Michelle Mengeling², Heather Davila², Shylo Wardyn² and Samantha Solimeo², ¹University of Utah School of Medicine, Salt Lake City, UT, ²Department of Veterans Affairs, Iowa City VA HCS, Iowa City, IA
Background/Purpose: Dual-energy x-ray absorptiometry (DXA) is an important tool to identify Veterans with osteoporosis, assess fracture risk, and monitor treatment response. Variability in DXA acquisition,…
Abstract Number: 1997 • ACR Convergence 2023
A Randomized, Double-blind, Phase III Study to Compare SB16 (Proposed Denosumab Biosimilar) to Reference Denosumab in Patients with Postmenopausal Osteoporosis
Richard Eastell¹, Bente Langdahl², Yoon-Sok Chung³, Rafal Plebanski⁴, Edward Czerwinski⁵, Eva Dokoupilova⁶, Jerzy Supronik⁷, Jan Rosa⁸, Anna Rowińska-Osuch⁹, Ki-Hyun Baek¹⁰, Audrone Urboniene¹¹, Sohui Ahn¹², Younghee Rho¹² and Jisuk Ban¹², ¹University of Sheffield, Sheffield, United Kingdom, ²Aarhus University Hospital, Aarhus, Denmark, ³Ajou University Hospital, Suwon, South Korea, ⁴Klinika Zdrowej Kosci, Łódź, Poland, ⁵Futuremeds, Krakowskie Centrum Medyczne sp z oo, Krakow, Poland, ⁶Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology; MEDICAL PLUS sro, Brno, Czech Republic, ⁷OsteoMedic sc A Racewicz J Supronik, Bialystok, Poland, ⁸Affidea Praha, s.r.o.; Faculty of Medicine in Hradec Kralove, Charles University, Prague; Hradec Kralove, Czech Republic, ⁹ETG Warszawa, Warszawa, Poland, ¹⁰Yeouido ST. Mary's Hospital, Seoul, South Korea, ¹¹JSC Saules seimos medicinos centras, Kaunas, Lithuania, ¹²Samsung Bioepis, Incheon, South Korea
Background/Purpose: SB16 is a human monoclonal antibody to the receptor activator of nuclear factor κΒ ligand that has been developed as a proposed biosimilar to…
Abstract Number: 2000 • ACR Convergence 2023
Efficacy of Romosozumab for Glucocorticoid-induced Osteoporosis in Patients with Rheumatic Diseases; A Prospective Study
Mai Kawazoe¹, Kaichi Kaneko², Shotaro Masuoka³, Soichi yamada³, Zento Yamada³, Sei Muraoka³, Karin Furukawa¹, Hiroshi Sato³, Eri Watanabe³, Keiko Koshiba³, Izumi Irita³, Miwa Kanaji³ and Toshihiro Nanki¹, ¹Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Ota-ku, Japan, ²Division of Rheumatology, Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan, ³Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan
Background/Purpose: Glucocorticoids are widely used to treat a variety of diseases, including rheumatic diseases. Although glucocorticoids improve the outcome for these diseases, various side effects…
Abstract Number: 2003 • ACR Convergence 2023
Effects of Abaloparatide on Cortical and Trabecular Compartments by 3D-DXA in Men with Osteoporosis
Ruban Dhaliwal¹, John Boxberger², Yamei Wang², Bruce Mitlak², Ludovic Humbert³ and Neil Binkley⁴, ¹Massachusetts General Hospital, Boston, MA, ²Radius Health, Inc., Boston, MA, ³3D-Shaper Medical, Barcelona, Spain, ⁴University of Wisconsin Osteoporosis Clinical Research Program, Madison, WI
Background/Purpose: Abaloparatide (ABL) increases BMD in men with osteoporosis. In the Abaloparatide for the Treatment of Men with Osteoporosis (ATOM) trial, DXA-measured BMD change with…
Abstract Number: 2007 • ACR Convergence 2023
Effects of IL-17 Blockade on Skeletal Microarchitecture in Patients with Axial Spondyloarthritis: An HR-pQCT Study
Insa Mannstadt, Donald McMahon, Douglas Mintz, Weija Yuan, Linda Russell, Susan Goodman, Emily Stein and Dalit Ashany, Hospital for Special Surgery, New York, NY
Background/Purpose: Axial spondyloarthritis (AxSpA), a chronic inflammatory rheumatic disease causes abnormal bone growth at the spine and paradoxically has been linked to osteoporosis and fragility…
Abstract Number: 2011 • ACR Convergence 2023
Predicting Fractures in Patients with Isolated Lumbar Spine Osteoporosis Compared to Those with Isolated Hip Osteoporosis
Nicholas Rossi¹, Aamir Saeed², Aqib Khan³, Hamzah Amin², Ummaz Nadeem², Zain Sultan³ and Marwan Bukhari², ¹University Hospitals of Morecambe Bay Foundation Trust, Worksop, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³University Hospitals of Morecambe Bay Foundation Trust, Lancaster, United Kingdom
Background/Purpose: Osteoporosis (OP) presents with fragility fractures, which can cause significant disability and cost to health services globally. There has been extensive research looking at…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.